Search hospitals > Minnesota > New Ulm
New Ulm Medical Center
Claim this profileNew Ulm, Minnesota 56073
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
268 reported clinical trials
9 medical researchers
Summary
New Ulm Medical Center is a medical facility located in New Ulm, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. New Ulm Medical Center is involved with conducting 268 clinical trials across 441 conditions. There are 9 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park7 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
98 reported clinical trials
160 drugs studied
Daniel M. AndersonRegions Hospital4 years of reported clinical research
Expert in Cancer
Expert in Tumors
60 reported clinical trials
108 drugs studied
Yan JiRegions Hospital1 year of reported clinical research
Expert in Cancer
Studies Breast Cancer
30 reported clinical trials
74 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park5 years of reported clinical research
Studies Cancer
Studies Tumors
14 reported clinical trials
19 drugs studied
Clinical Trials running at New Ulm Medical Center
Breast Cancer
Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Tumors
Multiple Myeloma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at New Ulm Medical Center?
New Ulm Medical Center is a medical facility located in New Ulm, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. New Ulm Medical Center is involved with conducting 268 clinical trials across 441 conditions. There are 9 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.